428 related articles for article (PubMed ID: 24418325)
1. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
3. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
[TBL] [Abstract][Full Text] [Related]
4. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
6. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Vangala JR; Dudem S; Jain N; Kalivendi SV
J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Kuhn DJ; Hunsucker SA; Chen Q; Voorhees PM; Orlowski M; Orlowski RZ
Blood; 2009 May; 113(19):4667-76. PubMed ID: 19050304
[TBL] [Abstract][Full Text] [Related]
8. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
Martinez-Gamboa L; Lesemann K; Kuckelkorn U; Scheffler S; Ghannam K; Hahne M; Gaber-Elsner T; Egerer K; Naumann L; Buttgereit F; Dörner T; Kloetzel PM; Burmester GR; Faustman DL; Feist E
J Rheumatol; 2013 May; 40(5):663-73. PubMed ID: 23504381
[TBL] [Abstract][Full Text] [Related]
11. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
12. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
13. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
[TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Busse A; Kraus M; Na IK; Rietz A; Scheibenbogen C; Driessen C; Blau IW; Thiel E; Keilholz U
Cancer; 2008 Feb; 112(3):659-70. PubMed ID: 18181098
[TBL] [Abstract][Full Text] [Related]
16. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
18. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]